AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26393904 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (tamsulosin 0.4 mg and placebo)
Number of subjects: 80
Study 26393904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 80
Study 26393904 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 80
Study 24613655 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 91
Study 24613655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 22315282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose BH4 (400 mg/d)
Number of subjects: 49
Study 22315282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BH4 (700 mg/d)
Number of subjects: 49
Study 22315282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 19897803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 μg
Number of subjects: 692
Study 19897803 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hydromorphone 1 mg IV and 1 mg IM
Number of subjects: 692
Study 19897803 — intervention group
Group type: COMPARATOR
Intervention: Neuraxial analgesia (combined spinal-epidural)
Number of subjects: 692
Study 19897803 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 692
Study 18569914 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 300,000 IU cholecalciferol supplementation
Number of subjects: 40
Study 18569914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 40
Study 15747245 — intervention group
Group type: EXPERIMENTAL
Intervention: rA2cp248/404/1030 Delta SH
Number of subjects: 44
Study 15747245 — intervention group
Group type: COMPARATOR
Intervention: rA2cp248/404 Delta SH
Number of subjects: 44
Study 11909785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297
Study 11909785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study 10695779 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg single dose of oral dihydroartemisinin (DHA)
Number of subjects: 8
Study 8961361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 325 mg daily for 1 year
Number of subjects: 186
Study 8961361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 8961361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 186
Study 1901203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 1901203 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study 1901203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium-imipramine combination
Number of subjects: 0
Study 1901203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6349943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone valerate 0.2 percent ointment
Number of subjects: 145
Study 31115908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks (Q2W)
Number of subjects: 0
Study 31115908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg Q2W
Number of subjects: 0
Study 31115908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 mg/kg Q2W (global population)
Number of subjects: 0
Study 31115908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (general)
Number of subjects: 0
Study 27188759 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic messaging intervention
Number of subjects: 200
Study 27188759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic messaging)
Number of subjects: 200
Study 27697128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated telephone follow-up after discharge
Number of subjects: 224
Study 27697128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone follow-up)
Number of subjects: 224
Study 25091664 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine (10^5.0 FFU)
Number of subjects: 120
Study 25091664 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine (10^5.8 FFU)
Number of subjects: 120
Study 25091664 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-TV vaccine (10^6.4 FFU)
Number of subjects: 120
Study 25091664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotateq
Number of subjects: 120
Study 25091664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23176247 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids, gamma-linolenic acid, and antioxidants
Number of subjects: 272
Study 23176247 — intervention group
Group type: COMPARATOR
Intervention: isocaloric control
Number of subjects: 272
Study 19717345 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (n=251)
Number of subjects: 504
Study 19717345 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy (n=253)
Number of subjects: 504
Study 17610441 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic social care management (CA Program)
Number of subjects: 781
Study 17610441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 781
Study 16389497 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First program
Number of subjects: 197
Study 16389497 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 197
Study 11917277 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg) administered before each chemotherapy cycle in the phase II trial and before carboplatin administration in the intensification trial.
Number of subjects: 646
Study 11917277 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (60 Gy) and carboplatin (700 mg/m² cumulative dose) without amifostine in the control group of the phase II trial.
Number of subjects: 646
Study 11917277 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (70 mg/m²) on specific days during radiotherapy in the intensification trial.
Number of subjects: 646
Study 11917277 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine combined with RCT in the long-term follow-up investigation.
Number of subjects: 646
Study 11917277 — intervention group
Group type: COMPARATOR
Intervention: RCT without cytoprotection in the long-term follow-up investigation.
Number of subjects: 646
Study 10498383 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital controller
Number of subjects: 6
Study 10498383 — intervention group
Group type: COMPARATOR
Intervention: Analog controller
Number of subjects: 6
Study 7503066 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 25 mg/kg
Number of subjects: 18
Study 7503066 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 50 mg/kg
Number of subjects: 18
Study 7503066 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb 100 mg/kg
Number of subjects: 18
Study 7503066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7503066 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb (all doses)
Number of subjects: 18
Study 2048706 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 0
Study 2048706 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 0
Study 2048706 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 7262758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 0
Study 7262758 — intervention group
Group type: COMPARATOR
Intervention: Conray EV
Number of subjects: 0
Study 7262758 — intervention group
Group type: COMPARATOR
Intervention: Tele-brix 300
Number of subjects: 0
Study 7262758 — intervention group
Group type: COMPARATOR
Intervention: Amipaque
Number of subjects: 0
Study 31609433 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 157
Study 31609433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 27658562 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing sutures
Number of subjects: 1633
Study 27658562 — intervention group
Group type: COMPARATOR
Intervention: Ordinary absorbing sutures
Number of subjects: 1633
Study 25456838 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 42
Study 23849608 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopolymerized acrylic resin with silanated attachment housings (APSAH)
Number of subjects: 80
Study 23849608 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopolymerized acrylic resin (APAR)
Number of subjects: 80
Study 23849608 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐polymerized acrylic resin (LPAR)
Number of subjects: 80
Study 23849608 — intervention group
Group type: EXPERIMENTAL
Intervention: Light‐polymerized acrylic resin with silanated attachment housings (LPSAH)
Number of subjects: 80
Study 22448480 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-glass test (Mearls and Stamey)
Number of subjects: 177
Study 22448480 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-glass test before finger rectal test (FRT)
Number of subjects: 177
Study 22448480 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-glass test
Number of subjects: 177
Study 22448480 — intervention group
Group type: EXPERIMENTAL
Intervention: Original technique proposed by the authors
Number of subjects: 177
Study 19504490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic prophylaxis (either UFH or LMWH)
Number of subjects: 14
Study 19504490 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 14
Study 19504490 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 14
Study 28080292 — intervention group
Group type: EXPERIMENTAL
Intervention: endOclear device
Number of subjects: 40
Study 28080292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 40
Study 19731498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol-reduction intervention
Number of subjects: 0
Study 19731498 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of change (SOC)
Number of subjects: 0
Study 10699772 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 50
Study 10699772 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 50
Study 9330936 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion (2 ng/kg/min for 8 hours)
Number of subjects: 26
Study 9330936 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (9 infusions over 6 months)
Number of subjects: 26
Study 9330936 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (40 mg/day for 6 months)
Number of subjects: 26
Study 8104656 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated sulphasalazine (SASP)
Number of subjects: 39
Study 8104656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3519382 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (200 mg IV four times a day for 7 days)
Number of subjects: 120
Study 3519382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30289950 — intervention group
Group type: EXPERIMENTAL
Intervention: SCARB1 SNP rs10846744
Number of subjects: 0
Study 30289950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp‐PLA2 activity
Number of subjects: 0
Study 30289950 — intervention group
Group type: COMPARATOR
Intervention: Darapladib (Lp‐PLA2 inhibitor)
Number of subjects: 0
Study 26605966 — intervention group
Group type: EXPERIMENTAL
Intervention: BW10-Group (feedback provided when errors were larger than 10°)
Number of subjects: 48
Study 26605966 — intervention group
Group type: COMPARATOR
Intervention: BW0-Group (100% frequency of feedback)
Number of subjects: 48
Study 26605966 — intervention group
Group type: EXPERIMENTAL
Intervention: YokedBW10-Group (matched to feedback schedule of BW10-Group)
Number of subjects: 48
Study 25325204 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/day of vitamin D
Number of subjects: 60
Study 25325204 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day of vitamin D
Number of subjects: 60
Study 22543771 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature fluid (BTF)
Number of subjects: 86
Study 22543771 — intervention group
Group type: COMPARATOR
Intervention: Room temperature fluid (RTF)
Number of subjects: 86
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: Other carcinogenic HPV
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV52
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV51
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16-positive CIN3
Number of subjects: 608
Study 20615885 — intervention group
Group type: EXPERIMENTAL
Intervention: Other carcinogenic HPV genotypes
Number of subjects: 608
Study 18415679 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) testing for bacterial gastroenteritis
Number of subjects: 153
Study 18415679 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) testing for bacterial gastroenteritis
Number of subjects: 153
Study 18415679 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT levels in patients with renal impairment
Number of subjects: 153
Study 18415679 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT levels in inflammatory bowel disease (IBD) patients
Number of subjects: 153
Study 15712536 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial lumbar puncture and acetazolamide combination
Number of subjects: 18
Study 12540416 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk drink (65 mL with Lactobacillus GG, Bifidobacterium sp B420, Lactobacillus acidophilus 145, and Streptococcus thermophilus; n = 108)
Number of subjects: 209
Study 12540416 — intervention group
Group type: COMPARATOR
Intervention: Standard yogurt (180 g; n = 101)
Number of subjects: 209
Study 12540416 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk drink
Number of subjects: 209
Study 12540416 — intervention group
Group type: COMPARATOR
Intervention: Standard yogurt
Number of subjects: 209
Study 10813378 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 20
Study 10813378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8858355 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS Plus with heparin and dexamethasone (HD)
Number of subjects: 62
Study 8858355 — intervention group
Group type: COMPARATOR
Intervention: BSS Plus (control)
Number of subjects: 62
Study 1516609 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alprazolam (1 mg)
Number of subjects: 12
Study 1516609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual alprazolam (1 mg)
Number of subjects: 12
Study 1516609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 12
Study 1516609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sublingual)
Number of subjects: 12
Study 1516609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of alprazolam (oral and sublingual)
Number of subjects: 12
Study 6384291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet A (UVA) added to ultraviolet B (UVB) phototherapy
Number of subjects: 25
Study 6384291 — intervention group
Group type: COMPARATOR
Intervention: Ultraviolet B (UVB) phototherapy alone
Number of subjects: 25
Study 31734125 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally‐tailored educational curriculum around stroke risk reduction
Number of subjects: 225
Study 31734125 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 225
Study 30060707 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 141
Study 30060707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin sponge patch
Number of subjects: 141
Study 30060707 — intervention group
Group type: COMPARATOR
Intervention: Observation (spontaneous healing)
Number of subjects: 141
Study 27219531 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated therapeutic alliance
Number of subjects: 209
Study 27219531 — intervention group
Group type: COMPARATOR
Intervention: Therapist-rated therapeutic alliance
Number of subjects: 209
Study 27219531 — intervention group
Group type: EXPERIMENTAL
Intervention: Two well-validated measures of depression symptom severity
Number of subjects: 209
Study 24669146 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose‐K contact lenses
Number of subjects: 60
Study 24669146 — intervention group
Group type: COMPARATOR
Intervention: Soper contact lenses
Number of subjects: 60
Study 22311004 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide (V/HCTZ)
Number of subjects: 384
Study 22311004 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 384
Study 22311004 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (V)
Number of subjects: 384
Study 20047095 — intervention group
Group type: EXPERIMENTAL
Intervention: idarubicin and cytosine arabinoside (IDR/Ara-C)
Number of subjects: 120
Study 20047095 — intervention group
Group type: COMPARATOR
Intervention: low-dose cytosine arabinoside and aclarubicin (CA)
Number of subjects: 120
Study 18663736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 30
Study 18663736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16297779 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoGam (n = 13)
Number of subjects: 23
Study 16297779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 23
Study 12454227 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 15
Study 12454227 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac infusion
Number of subjects: 15
Study 10527007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive
Number of subjects: 440
Study 10527007 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire (one page)
Number of subjects: 440
Study 10527007 — intervention group
Group type: COMPARATOR
Intervention: Long questionnaire (seven pages)
Number of subjects: 440
Study 8719592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 36
Study 8719592 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 1952037 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with extubation during anesthesia
Number of subjects: 40
Study 1952037 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia with extubation during anesthesia
Number of subjects: 40
Study 1952037 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with awake extubation
Number of subjects: 40
Study 1952037 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia with awake extubation
Number of subjects: 40
Study 1952037 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation during anesthesia
Number of subjects: 40
Study 1952037 — intervention group
Group type: COMPARATOR
Intervention: Awake extubation
Number of subjects: 40
Study 7282427 — intervention group
Group type: EXPERIMENTAL
Intervention: ceruletide 0.3 microgram/kg intramuscularly
Number of subjects: 148
Study 7282427 — intervention group
Group type: EXPERIMENTAL
Intervention: ceruletide 0.03 microgram/kg intravenously
Number of subjects: 148
Study 7282427 — intervention group
Group type: EXPERIMENTAL
Intervention: ceruletide 0.05 microgram/kg intravenously
Number of subjects: 148
Study 7282427 — intervention group
Group type: COMPARATOR
Intervention: cholecystokinin
Number of subjects: 148
Study 31665842 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-in-one asthma management model (standardized asthma treatment, asthma diary, PEF monitoring, reasonable diet and physical exercise)
Number of subjects: 59
Study 31665842 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-in-one asthma management model
Number of subjects: 59
Study 31665842 — intervention group
Group type: COMPARATOR
Intervention: Routine medication and regular outpatient consultation (control group)
Number of subjects: 59
Study 27855493 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-damaging exercise performed during visit 3
Number of subjects: 20
Study 27855493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no muscle-damaging exercise)
Number of subjects: 20
Study 25420010 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise program aimed at increasing the size of the intervertebral foramen (IVF) of the affected nerve root
Number of subjects: 36
Study 25420010 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and exercise program without the specific goal of increasing the size of the IVF
Number of subjects: 36
Study 25420010 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and exercise program aimed at increasing the size of the IVF of the affected nerve root
Number of subjects: 36
Study 23831221 — intervention group
Group type: EXPERIMENTAL
Intervention: K-115 0.1%
Number of subjects: 210
Study 23831221 — intervention group
Group type: EXPERIMENTAL
Intervention: K-115 0.2%
Number of subjects: 210
Study 23831221 — intervention group
Group type: EXPERIMENTAL
Intervention: K-115 0.4%
Number of subjects: 210
Study 23831221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 21505984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (conventional therapy plus continuous insulin pumping to control blood glucose at 4.4‐6.1 mmol/L)
Number of subjects: 114
Study 21505984 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 114
Study 19409038 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib + Docetaxel/Prednisolone (DP)
Number of subjects: 86
Study 19409038 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Docetaxel/Prednisolone (DP)
Number of subjects: 86